Bayer's Xofigo Is For Routine NHS Use, NICE Says
Executive Summary
Bayer’s prostate cancer radiotherapeutic is recommended by the health technology regulator for non-docetaxel treated patients, widening its likely use and improving its market potential.
You may also be interested in...
NICE, In Reversal, Rejects Ferring’s Firmagon But Backs Bayer’s Xofigo
The British health tech assessment agency reverses an initial restricted green light for Ferring’s prostate cancer drug after experts urged a re-evaluation. But Bayer’s prostate cancer therapy Xofigo gets a provisional go-ahead.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.